De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Corpovael. de Toekomstige groei

Future criteriumcontroles 3/6

De verwachting is dat Corpovael. de de winst en omzet met respectievelijk 18.5% en 6.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 7.3% per jaar.

Belangrijke informatie

22.1%

Groei van de winst

21.8%

Groei van de winst per aandeel

Consumer Durables winstgroei	25.4%
Inkomstengroei	6.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	16 Oct 2024

Recente toekomstige groei-updates

Recent updates

Returns On Capital Signal Difficult Times Ahead For Corpovael. de (BMV:CADUA)

Jun 05

Corpovael, S.A.B. de C.V.'s (BMV:CADUA) Earnings Haven't Escaped The Attention Of Investors

Jan 18

These 4 Measures Indicate That Corpovael. de (BMV:CADUA) Is Using Debt Extensively

May 05

Corpovael. de (BMV:CADUA) Might Be Having Difficulty Using Its Capital Effectively

Jul 16

Corpovael. de's (BMV:CADUA) Soft Earnings Don't Show The Whole Picture

May 05

These 4 Measures Indicate That Corpovael. de (BMV:CADUA) Is Using Debt In A Risky Way

Apr 29

A Look At The Intrinsic Value Of Corpovael, S.A.B. de C.V. (BMV:CADUA)

Apr 02

The Returns At Corpovael. de (BMV:CADUA) Provide Us With Signs Of What's To Come

Mar 12

How Much Did Corpovael. de's(BMV:CADUA) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 19

Here's Why Corpovael. de (BMV:CADUA) Is Weighed Down By Its Debt Load

Jan 15

What Do The Returns On Capital At Corpovael. de (BMV:CADUA) Tell Us?

Dec 11

Winst- en omzetgroeiprognoses

BMV:CADU A - Toekomstschattingen van analisten en financiële gegevens uit het verleden (MXN Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	5,084	441	326	272	1
12/31/2025	4,993	360	377	43	2
12/31/2024	4,504	259	N/A	318	1
9/30/2024	4,462	190	768	773	N/A
6/30/2024	4,307	267	434	440	N/A
3/31/2024	4,304	290	860	862	N/A
12/31/2023	4,506	296	1,311	1,313	N/A
9/30/2023	4,588	460	1,680	1,689	N/A
6/30/2023	4,405	380	1,821	1,828	N/A
3/31/2023	4,230	359	1,540	1,552	N/A
12/31/2022	3,727	259	1,000	1,007	N/A
9/30/2022	2,893	-198	76	77	N/A
6/30/2022	2,848	-157	99	100	N/A
3/31/2022	2,580	-204	2	3	N/A
12/31/2021	2,779	-104	283	284	N/A
9/30/2021	3,552	190	926	928	N/A
6/30/2021	3,581	135	1,038	1,040	N/A
3/31/2021	3,378	140	1,180	1,182	N/A
12/31/2020	3,297	152	768	770	N/A
9/30/2020	3,004	52	677	684	N/A
6/30/2020	3,352	239	427	433	N/A
3/31/2020	4,112	430	265	272	N/A
12/31/2019	4,304	516	384	391	N/A
9/30/2019	4,630	814	-212	-181	N/A
6/30/2019	4,797	837	-348	-318	N/A
3/31/2019	4,869	843	-365	-331	N/A
12/31/2018	4,626	778	-195	-161	N/A
9/30/2018	4,793	785	-35	-6	N/A
6/30/2018	4,746	757	N/A	211	N/A
3/31/2018	4,595	724	N/A	539	N/A
12/31/2017	4,507	711	N/A	201	N/A
9/30/2017	4,145	620	N/A	60	N/A
6/30/2017	3,873	564	N/A	-279	N/A
3/31/2017	3,761	557	N/A	-631	N/A
12/31/2016	4,022	581	N/A	-617	N/A
9/30/2016	3,764	542	N/A	-531	N/A
6/30/2016	3,612	517	N/A	-525	N/A
3/31/2016	3,550	461	N/A	-318	N/A
12/31/2015	3,523	428	N/A	-421	N/A
9/30/2015	3,891	459	N/A	-125	N/A
6/30/2015	3,992	453	N/A	-35	N/A
3/31/2015	3,619	402	N/A	-136	N/A
12/31/2014	3,189	334	N/A	-83	N/A
9/30/2014	2,793	221	N/A	-73	N/A
6/30/2014	2,613	199	N/A	260	N/A
3/31/2014	2,539	222	N/A	387	N/A
12/31/2013	2,608	291	N/A	319	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CADU A ( 18.5% per jaar) ligt boven de spaarquote ( 7.9% ).

Winst versus markt: De winst van CADU A ( 18.5% per jaar) zal naar verwachting sneller groeien dan de MX markt ( 11.1% per jaar).

Hoge groeiwinsten: De winst van CADU A zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van CADU A ( 6.6% per jaar) zal naar verwachting langzamer groeien dan de markt MX ( 7% per jaar).

Hoge groei-inkomsten: De omzet van CADU A ( 6.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CADU A naar verwachting over 3 jaar hoog zal zijn

Corpovael. de Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 44% to Mex$7.50

Price target decreased to Mex$4.00

Price target decreased to Mex$5.10

Price target decreased to Mex$4.60

Price target decreased to Mex$6.30

Price target decreased to Mex$7.17

Recent updates

Third quarter 2024 earnings released: EPS: Mex$0.11 (vs Mex$0.34 in 3Q 2023)

Second quarter 2024 earnings released: EPS: Mex$0.20 (vs Mex$0.27 in 2Q 2023)

Returns On Capital Signal Difficult Times Ahead For Corpovael. de (BMV:CADUA)

First quarter 2024 earnings released: EPS: Mex$0.21 (vs Mex$0.23 in 1Q 2023)

Price target increased by 44% to Mex$7.50

Now 21% overvalued after recent price rise

Now 20% overvalued after recent price rise

Full year 2023 earnings released: EPS: Mex$0.93 (vs Mex$0.80 in FY 2022)

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Insufficient new directors

Corpovael, S.A.B. de C.V.'s (BMV:CADUA) Earnings Haven't Escaped The Attention Of Investors

Now 22% undervalued

Now 22% undervalued

Third quarter 2023 earnings released

Second quarter 2023 earnings released

New major risk - Revenue and earnings growth

These 4 Measures Indicate That Corpovael. de (BMV:CADUA) Is Using Debt Extensively

First quarter 2023 earnings released

Full year 2022 earnings released: EPS: Mex$0.84 (vs Mex$0.31 loss in FY 2021)

Price target decreased to Mex$4.00

Insufficient new directors

Third quarter 2022 earnings released

Here's Why Corpovael. de (BMV:CADUA) Has A Meaningful Debt Burden

Price target decreased to Mex$5.10

Less than half of directors are independent

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to Mex$4.60

Less than half of directors are independent

We Think Corpovael. de (BMV:CADUA) Is Taking Some Risk With Its Debt

Be Wary Of Corpovael. de (BMV:CADUA) And Its Returns On Capital

Full year 2021 earnings: EPS and revenues miss analyst expectations

We Think Corpovael. de (BMV:CADUA) Is Taking Some Risk With Its Debt

Investor sentiment deteriorated over the past week

Corpovael. de (BMV:CADUA) May Have Issues Allocating Its Capital

Third quarter 2021 earnings released: EPS Mex$0.21 (vs Mex$0.04 in 3Q 2020)

Price target decreased to Mex$6.30

Second quarter 2021 earnings released

Price target decreased to Mex$7.17

Corpovael. de (BMV:CADUA) Might Be Having Difficulty Using Its Capital Effectively

Corpovael. de's (BMV:CADUA) Soft Earnings Don't Show The Whole Picture

Investor sentiment improved over the past week

These 4 Measures Indicate That Corpovael. de (BMV:CADUA) Is Using Debt In A Risky Way

A Look At The Intrinsic Value Of Corpovael, S.A.B. de C.V. (BMV:CADUA)

Investor sentiment improved over the past week

The Returns At Corpovael. de (BMV:CADUA) Provide Us With Signs Of What's To Come

New 90-day low: Mex$4.04

How Much Did Corpovael. de's(BMV:CADUA) Shareholders Earn From Share Price Movements Over The Last Five Years?

Here's Why Corpovael. de (BMV:CADUA) Is Weighed Down By Its Debt Load

New 90-day low: Mex$4.49

What Do The Returns On Capital At Corpovael. de (BMV:CADUA) Tell Us?

New 90-day low: Mex$5.60

Third quarter earnings released

Price target lowered to Mex$8.00

Price target lowered to Mex$8.00

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven